term
gene
therapi
origin
coin
describ
approach
diseas
treatment
involv
genet
modif
initi
research
field
focus
introduct
gene
cell
achiev
therapeut
effect
howev
scope
gene
therapi
sinc
expand
includ
use
nucleic
acid
alter
gene
function
review
collin
et
sinc
way
gene
function
underli
normal
patholog
process
employ
technolog
specif
modifi
gene
function
util
treat
varieti
diseas
mani
condit
seriou
public
health
import
africa
thu
amen
treatment
use
gene
therapi
technolog
therefor
signific
manag
diseas
contin
despit
potenti
import
direct
research
topic
africa
limit
although
africa
good
researchintens
institut
contin
lose
skill
personnel
laboratori
north
america
europ
consequ
scarciti
capabl
molecular
biologist
carri
research
gene
therapi
strengthen
human
resourc
capac
prioriti
creat
platform
attract
qualifi
scientist
incentiv
train
african
scientist
remain
contin
date
investig
larg
involv
advanc
therapeut
nucleic
acid
manag
hepat
b
viru
hbv
particularli
power
featur
gene
therapi
design
candid
drug
base
ration
design
essenti
base
inform
nucleic
acid
recent
impress
progress
sequenc
technolog
coupl
advanc
broader
field
molecular
biolog
virolog
oncolog
synthet
chemistri
amongst
other
provid
valuabl
resourc
advanc
gene
therapi
design
novel
gene
therapi
becom
reliabl
improv
insight
lead
use
effici
standard
drug
develop
protocol
although
versatil
strategi
employ
gene
therapi
treat
diseas
requir
complex
labor
intens
time
consum
multistep
process
expens
implement
requir
sophist
infrastructur
compli
regulatori
requir
tabl
preclin
develop
special
skill
equip
requir
gene
therapeut
design
product
larg
scale
product
gene
therapeut
clinic
test
requir
facil
meet
requir
good
manufactur
practic
lack
import
factor
taken
account
consid
feasibl
gene
therapi
resourcepoor
set
africa
mani
differ
express
synthet
nucleic
acid
well
chemic
modifi
deriv
consid
gene
therapeut
concommit
broader
rang
gene
therapyact
molecul
diseas
consid
feasibl
therapeut
target
highli
vari
treatment
viral
infect
cancer
inherit
diseas
immunotherapi
within
realm
gene
technolog
howev
yet
wide
use
clinic
set
licens
usual
grant
particular
countri
exampl
gene
therapi
spinraza
treatment
spinal
muscular
gendicin
treatment
head
neck
squamou
cell
glybera
correct
lipoprotein
lipas
imlyg
treatment
melanoma
nevertheless
gene
therapi
reach
mainstream
diseas
treatment
like
import
manag
diseas
affect
african
contin
particularli
capac
develop
enabl
african
tackl
health
problem
africa
vital
futur
gene
therapi
contin
key
success
gene
therapi
program
africa
govern
endors
ensur
sustain
commun
engag
enact
appropri
regulatori
legisl
reward
entrepreneurship
although
mani
research
diagnost
laboratori
carri
work
gene
therapyaffili
scientif
topic
genet
analysi
african
popul
research
laboratori
africa
special
work
develop
gene
therapi
drug
africa
made
signific
progress
advanc
stem
cell
therapi
sever
laboratori
focu
therapeut
knowledg
antivir
gene
therapi
research
unit
south
african
medic
research
council
univers
witwatersrand
witssamrc
agtru
johannesburg
lab
africa
specialis
gene
therapi
research
institut
cellular
molecular
medicin
icmm
univers
pretoria
school
life
scienc
univers
kwazulunat
also
pursu
research
theme
topic
gene
therapi
issu
relat
shortag
human
resourc
discuss
fund
mainten
research
laboratori
limit
partnership
intern
collabor
contribut
problem
dearth
resourc
african
countri
complic
inequ
within
countri
exampl
south
africa
countri
highest
gini
coeffici
unequ
distribut
incom
translat
provis
health
care
markedli
favor
wealthi
ensur
fair
alloc
resourc
within
countri
contin
challeng
work
toward
distribut
justic
well
work
within
framework
sound
principl
health
econom
import
safeguard
benefit
hightechnolog
medicin
african
commun
littl
research
carri
estim
futur
benefit
implement
gene
therapi
africa
part
world
compound
fact
gene
therapeut
current
point
clearli
highlight
case
glybera
price
tag
approxim
u
singl
administr
similar
issu
regard
price
efficaci
imlyg
limit
widespread
rollout
strimv
cellbas
therapi
treatment
adenosin
deaminasesever
combin
immunodefici
appear
encourag
relat
robust
data
efficaci
therapeut
reason
price
furthermor
data
suggest
price
strimv
significantli
lower
altern
enzym
replac
therapi
field
matur
like
bring
modern
power
technolog
mainstream
medic
practic
lower
cost
gene
therapi
global
burden
diseas
chang
significantli
past
gener
trend
peopl
live
longer
death
result
communic
diseas
declin
mortal
noncommmunic
diseas
increas
chang
subsaharan
africa
howev
less
signific
although
noncommunic
diseas
increas
region
infecti
nutrit
perinat
infant
matern
diseas
remain
major
contributor
mortal
death
measl
tetanu
declin
significantli
throughout
region
howev
hivaid
malaria
infecti
hepat
tuberculosi
major
contributor
mortal
morbid
intervent
counter
burden
diseas
best
priorit
accord
cost
effect
mean
limit
morbid
mortal
commonest
diseas
attent
appropri
primari
health
care
vaccin
basic
sanit
behavior
modif
pre
postnat
care
greatest
impact
implement
gene
therapi
correctli
perceiv
costli
sophist
treatment
option
requir
care
assess
impact
intervent
concept
fals
dichotomi
global
apposit
consid
use
gene
therapi
africa
recent
public
frenk
gomezdant
propos
complex
global
healthcar
need
requir
integr
comprehens
strategi
effect
recent
health
prioriti
determin
appear
oppos
viewpoint
exampl
socal
dichotomi
includ
primari
oppos
special
care
prevent
versu
cure
integr
appar
polar
approach
howev
import
creat
synergi
improv
overal
manag
diseas
treatment
individu
easili
understood
exampl
illustr
point
although
effort
modifi
behavior
diminish
spread
viru
prognosi
untreat
individu
alreadi
infect
viru
grave
suppress
replic
use
combin
antiretrovir
therapi
dramat
improv
prognosi
render
individu
less
infecti
therefor
curtail
transmiss
howev
cure
infect
would
ideal
obviat
current
requir
longterm
administr
antiretrovir
advanc
gene
therapi
demonstr
cure
seriou
infect
possibl
discuss
detail
infect
progress
aid
emerg
seriou
public
health
problem
subsaharan
africa
still
particularli
serious
affect
pandem
approxim
death
region
result
aid
http
wwwwhointghohivepidemicstatusdeathstexten
improv
access
combin
antiretrovir
therapi
limit
aid
develop
individu
nevertheless
difficulti
elimin
viru
slow
progress
vaccin
strategi
meant
infect
complic
remain
signific
public
health
problem
africa
advanc
use
gene
therapi
achiev
durabl
suppress
replic
stimul
interest
appli
technolog
enthusiasm
gene
therapi
treat
infect
partli
deriv
success
elimin
socal
berlin
patient
bone
marrow
ablat
treat
acut
myeloid
leukemia
individu
receiv
allogen
bone
marrow
transplant
match
donor
homozyg
mutant
coreceptor
donor
cell
thu
resist
infect
berlin
patient
free
without
need
antiretrovir
although
particularli
impress
achiev
widespread
use
allogen
bone
marrow
transplant
problemat
difficulti
find
match
donor
doubl
mutat
address
problem
gene
edit
employ
attempt
disabl
render
autolog
cell
resist
repeat
cleavag
target
sequenc
lead
repair
errorpron
nonhomolog
end
join
eventu
mutat
target
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
ca
system
zinc
finger
nucleas
transcript
activatorlik
effector
nucleas
employ
achiev
targetspecif
cleavag
inhibit
replic
review
favor
strategi
employ
ex
vivo
modif
autolog
hematopoiet
stem
cell
figur
modifi
hematopoiet
stem
cell
may
expand
reinfus
patient
variat
procedur
induc
pluripot
stem
cell
may
use
underli
principl
stem
cell
retain
capabl
selfrenew
treat
individu
may
therefor
reconstitut
immun
system
compris
cell
resist
infect
viru
addit
mutat
host
factor
requir
entri
host
cell
strategi
aim
disabl
viral
sequenc
directli
also
although
inactiv
proviru
observ
deliveri
gene
editor
reservoir
latent
infect
cell
remain
challeng
har
rna
interfer
rnai
pathway
anoth
geneinactiv
strategi
investig
therapeut
applic
review
berkhout
et
gene
edit
artifici
rnai
activ
use
target
host
factor
viral
sequenc
imped
viral
sinc
rnai
activ
function
posttranscript
level
gene
express
longterm
action
gene
silenc
necessari
achiev
durabl
suppress
viral
replic
combinatori
approach
employ
counter
emerg
viral
escap
use
express
cassett
gener
mimic
rnai
pathway
may
thu
prefer
administr
synthet
exogen
rnai
activ
transient
effect
viral
replic
effect
sustain
express
rnai
activ
cellular
function
yet
comprehens
establish
unintend
offtarget
effect
may
well
occur
strategi
overcom
induct
immun
resons
dsrna
unintend
bind
exogen
rnai
effector
cellular
target
cytotox
satur
endogen
pathway
remain
import
chronic
infect
hbv
occur
million
peopl
infect
hyperendem
subsaharan
lifethreaten
complic
includ
cirrhosi
hepatocellular
carcinoma
occur
commonli
carrier
viru
although
effect
vaccin
avail
prevent
hbv
infect
therapeut
benefit
use
individu
alreadi
infect
viru
use
gene
transfer
induc
immun
viru
shown
promis
discuss
complic
chronic
hbv
infect
remain
signific
public
health
problem
particular
relev
africa
despit
widespread
vaccin
program
global
mortal
hbv
infect
increas
period
peopl
die
result
complic
hbv
avail
licens
therapi
hbv
infect
includ
revers
transcriptas
inhibitor
deriv
interferonalpha
drug
capabl
suppress
hbv
replic
rare
elimin
viru
virusinfect
individu
main
reason
shortcom
current
treatment
stabil
viral
replic
intermedi
compris
coval
close
circular
dna
cccdna
cccdna
serv
templat
express
viral
gene
unaffect
nucleosid
nucleotid
analog
rare
elimin
carrier
persist
viru
therefor
result
continu
risk
mortal
complic
cirrhosi
hepatocellular
carcinoma
research
appli
gene
therapi
treat
hbv
infect
show
promis
advanc
treatment
infect
gene
silenc
gene
edit
potenti
review
dever
et
ivacik
et
hbv
unusu
compact
genom
overlap
open
read
frame
result
cccdna
restrict
sequenc
plastic
unlik
viral
escap
unusu
target
cccdna
engin
sequencespecif
nucleas
zinc
finger
transcript
activatorlik
effector
provid
way
perman
disabl
replic
intermedi
sever
studi
shown
target
mutagenesi
disabl
hbv
dna
therebi
provid
mean
elimin
hbv
chronic
infect
individu
advanc
technolog
stage
evalu
clinic
set
current
prioriti
next
step
face
challeng
safe
effici
deliveri
therapeut
sequenc
hbvinfect
hepatocyt
follow
system
administr
figur
verifi
specif
action
gene
editor
sequenc
encod
potenti
therapeut
crisprca
dimer
zinc
finger
nucleas
transcript
activatorlik
effector
nucleas
long
easili
accommod
popular
adenoassoci
viral
vector
altern
approach
formul
mrna
encod
gene
editor
synthet
nonvir
vector
nvv
may
necessari
activ
rnai
therapeut
inhibit
hbv
gene
express
activ
field
research
review
ivacik
et
synthet
sirna
without
chemic
modif
incorpor
hepatotrop
nvv
use
success
inhibit
replic
express
rnai
activ
includ
short
hairpin
long
hairpin
multimer
artifici
microrna
mir
also
demonstr
good
efficaci
viru
interestingli
evid
express
short
hairpin
rna
capabl
inhibit
hbv
replic
vivo
first
demonstr
rnai
antivir
use
hbvtarget
rnai
activ
reach
stage
test
clinic
although
preclin
evalu
shown
promis
remain
establish
whether
longterm
efficaci
suffici
achiev
cure
gene
therapi
undoubtedli
potenti
cure
hbv
infect
howev
challeng
face
clinic
translat
gene
therapi
also
appli
hbv
treatment
effici
deliveri
avoid
toxic
limit
immunostimul
ensur
specif
action
import
largescal
use
patient
synthet
formul
like
necessari
use
subsaharan
africa
need
afford
stabl
easili
administ
regimen
includ
combin
licens
drug
gene
therapi
interest
evalu
may
improv
efficaci
sporad
outbreak
infect
hemorrhag
fever
virus
hfv
major
concern
part
subsaharan
africa
hemorrhag
fever
seriou
condit
character
sudden
onset
symptom
rapidli
progress
bleed
shock
multiorgan
failur
associ
high
mortal
ebola
viru
ebov
epidem
commenc
guinea
decemb
spread
liberia
sierra
leon
particularli
sever
viru
claim
live
excess
peopl
west
africa
http
marburg
viru
anoth
member
filoviru
famili
hfv
encount
frequent
africa
given
often
lethal
natur
infect
hfv
potenti
global
impact
develop
vaccin
effect
antivir
understand
prioriti
earli
clinic
featur
viral
hemorrhag
fever
usual
pathognomon
infect
earli
diagnosi
therefor
difficult
manag
current
limit
support
contain
infect
individu
vital
prevent
spread
ration
design
form
basi
gene
therapi
particularli
use
disabl
hfv
mani
investig
shown
gene
therapi
promis
treatment
seriou
infect
pathogen
caus
hemorrhag
fever
rna
virus
replic
cytoplasm
infect
cell
exploit
rnai
inactiv
replic
therefor
logic
approach
advanc
gene
therapi
treat
infect
howev
import
featur
infect
ebov
viral
protein
inhibit
rnai
overcom
effect
sequenc
target
strategi
employ
rnai
inhibit
ebov
given
acut
natur
hfv
infect
sustain
rnaimedi
silenc
less
import
hbv
infect
promis
preclin
studi
show
synthet
sirna
formul
hepatotrop
nvv
protect
macaqu
lethal
exposur
although
sever
differ
type
human
cell
permiss
infect
ebov
replic
viru
occur
mainli
liver
rational
use
hepatotrop
nvv
figur
approach
employ
rnai
disabl
replic
marburg
viru
also
shown
therapeut
potenti
synthet
sirna
formul
hepatotrop
nvv
afford
good
protect
guinea
rhesu
follow
lethal
challeng
rift
valley
fever
viru
anoth
potenti
seriou
hfv
also
shown
suscept
rnaibas
seriou
natur
infect
ebov
marburg
viru
make
impract
evalu
new
drug
treat
infect
convent
clinic
trial
unit
state
food
drug
administr
thu
devis
anim
rule
review
enabl
clinic
use
drug
show
good
efficaci
anim
studi
sinc
efficaci
nucleic
acidbas
treatment
ebov
marburg
viru
convincingli
demonstr
macaqu
case
initi
gene
therapi
treat
hfv
infect
compel
although
commend
practic
issu
relat
rapid
implement
larg
scale
affect
african
popul
may
current
difficult
recent
outbreak
ebov
highlight
anim
rule
could
employ
effort
underway
fasttrack
candid
vaccin
engag
african
intern
stakehold
facilit
howev
sinc
clinic
data
efficaci
normal
requir
licens
intervent
never
use
ebov
endors
merit
pursu
less
tradit
licens
rout
anim
rule
mani
year
vaccin
cornerston
protect
infecti
diseas
rational
administr
immunogen
may
recombin
protein
kill
attenu
pathogen
induc
memor
immun
pathogen
without
risk
diseas
deliveri
nucleic
acid
may
engin
within
recombin
viral
vector
synthet
formul
recent
gain
popular
immunogen
use
dna
encod
immunogen
activ
field
earli
studi
show
use
approach
prevent
hbv
recombin
virus
engin
replic
defect
adenovirus
ad
poxvirus
review
gain
popular
vector
deliv
immunogen
sequenc
effici
capabl
induc
power
cytotox
lymphocyt
respons
ad
poxvirus
well
understood
possibl
manipul
genom
encod
variou
immunogen
confer
varieti
prefer
biolog
properti
drawback
recombin
viral
vector
immunogen
step
hiv
vaccin
trial
highlight
particularli
seriou
consequ
immunostimulatori
effect
vaccin
term
compris
serotyp
ad
vector
encod
gag
pol
nef
sequenc
subtyp
b
initi
studi
entail
administr
vaccin
nonafrican
resid
part
world
clade
b
predomin
subtyp
contrari
intend
effect
patient
receiv
vaccin
slightli
higher
risk
acquir
infect
effect
may
result
predelict
cell
activ
vaccin
subsequ
trial
analyz
administr
south
african
subject
clade
c
studi
howev
halt
outcom
step
trial
becam
although
earli
termin
investig
limit
abil
draw
conclus
vaccin
appear
prevent
infect
south
african
subsequ
investig
attempt
augment
immunogen
employ
primeboost
strategi
individu
south
subject
initi
receiv
dna
vaccin
encod
gag
pol
nef
clade
b
env
clade
b
c
recombin
clade
b
gagpol
fusion
env
clade
b
c
theraft
given
booster
although
vaccin
regimen
induc
humor
cellmedi
immun
respons
prevent
viral
infect
establish
anoth
consider
relev
develop
vaccin
preexist
immun
adenovirus
serotyp
occur
commonli
vaccin
distinct
bypass
immun
thu
test
clinic
trial
develop
vaccin
major
advantag
employ
nucleic
acid
transfer
rather
recombin
protein
administr
cellmedi
well
humor
immun
induc
express
immunogen
within
cell
simul
pathogen
gene
express
infect
cell
encod
protein
may
present
cell
surfac
major
histocompat
complex
class
receptor
turn
lead
activ
cytotox
cell
recombin
protein
typic
humor
arm
immun
respons
activ
occur
follow
major
histocompat
complex
class
iimedi
interact
antigenpres
cell
helper
cell
stimul
b
cell
matur
form
antibodyproduc
plasma
cell
follow
intramuscular
intraderm
administr
nucleic
acid
vector
myocyt
dendrit
cell
monocyt
may
take
express
encod
immunogen
result
major
histocompat
complex
class
major
histocompat
complex
class
ii
activ
stimul
cytotox
cell
prolifer
plasma
cell
effect
activ
cellmedi
humor
prevent
therapeut
immun
use
gene
transfer
mani
advantag
particularli
relev
african
set
includ
follow
vaccin
gener
safe
toxic
nucleic
acid
formul
within
synthet
nvv
usual
antigenicmanipul
prepar
dna
employ
procedur
standard
prepar
suffici
amount
requir
widespread
vaccin
program
typic
uncomplicatedincorpor
addit
sequenc
augment
immunostimul
feasibleit
possibl
includ
adjuv
oligonucleotid
activ
tolllik
receptor
enhanc
immunostimul
immunomodulatori
effect
use
gene
trasnfer
also
gain
popular
cancer
treatment
use
gene
therapi
adapt
principl
passiv
immun
also
util
sequenc
encod
broadli
neutral
antibodi
nnab
activ
rang
isol
incorpor
recombin
adenoassoci
viral
approach
term
vector
immunoprophylaxi
capabl
protect
hiv
challeng
human
mice
myriad
inherit
diseas
particular
africa
african
diaspora
led
global
dispers
although
variabl
distribut
throughout
africa
two
common
inherit
disord
contin
sickl
cell
diseas
defici
sickl
cell
diseas
result
homozyg
transvers
substitut
first
exon
gene
review
hossain
et
affect
codon
chang
sequenc
encod
valin
amino
acid
instead
glutam
acid
heterozyg
state
sickl
gene
provid
protect
malaria
mechan
thought
involv
preferenti
remov
plasmodium
falciparuminfect
red
blood
cell
macrophag
homozyg
mutat
result
seriou
patholog
manifest
sickl
cell
diseas
sickl
red
blood
cell
result
polymer
hemoglobin
follow
deoxygen
red
blood
cell
short
life
span
caus
endotheli
end
organ
damag
result
high
mortal
morbid
allogen
stem
cell
transplant
use
success
treat
sickl
cell
diseas
find
match
donor
difficult
investig
use
gene
therapi
counter
defect
thu
becom
popular
line
research
review
marimani
et
safe
effici
globin
gene
express
togeth
appropri
regul
transgen
express
progenitor
red
blood
cell
vital
gene
addit
target
cell
express
altern
globin
gene
reactiv
fetal
globin
gene
gene
edit
investig
therpaeut
option
two
promis
approach
entail
gene
edit
inactiv
stimul
homolog
direct
repair
restor
normal
sequenc
repressor
gene
express
adult
monoallel
inactiv
target
within
gene
increas
express
achiev
therapeut
applic
autolog
hematopoiet
stem
cell
modif
reinfus
figur
also
feasibl
mode
treatment
gene
therapi
primari
immunodefici
current
area
vigor
research
although
gene
therapi
primari
immunodefici
africa
receiv
littl
attent
program
manag
primari
immunodefici
africa
establish
http
wwwsunaczaenglishfacultyhealthsciencesmolecularbiologyhumangeneticspiddgen
capabl
may
provid
entri
point
establish
gene
therapi
platform
may
also
use
facilit
treatment
common
diseas
discuss
gene
therapi
complex
field
demand
materi
human
resourc
adequ
fund
strateg
partnership
thu
essenti
provid
base
facilit
meaning
progress
africa
govern
support
variabl
throughout
contin
inform
readili
avail
specif
detail
resourc
devot
advanc
gene
therapi
contin
south
african
fund
agenc
particularli
gener
back
includ
south
african
medic
research
council
nation
research
foundat
depart
scienc
technolog
fund
come
outsid
africa
typic
provid
research
partnership
involv
african
research
also
valuabl
us
nation
institut
health
nih
wellcom
trust
european
commiss
sponsor
team
includ
african
research
work
gene
therapi
initi
http
shine
exampl
properli
channel
monitor
intern
fund
use
effect
build
capac
field
relat
gene
therapi
requir
support
fund
agenc
princip
investig
resid
african
contin
shehe
address
problem
relev
peopl
program
receiv
fund
nih
wellcom
trust
first
round
fund
initi
second
round
also
support
glaxosmithklin
gsk
london
uk
began
second
round
fund
administ
allianc
acceler
excel
scienc
africa
aesa
http
initi
african
academi
scienc
aa
new
partnership
africa
develop
nepad
agenc
aesa
recent
also
solicit
applic
grand
challeng
africa
gca
http
aasciencesackeaesaenprogrammesgrandchallengesafrica
aim
promot
afric
scientif
innov
help
countri
better
achiev
sustain
develop
goal
award
seed
full
grant
contin
impress
solut
fund
gca
initi
provid
bill
melinda
gate
foundat
african
initi
includ
support
gene
therapi
within
program
african
network
drug
diagnost
innov
andi
wwwandiafricaorg
http
wwwwhointtdrpartnershipsinitiativesandi
project
support
sever
partner
includ
world
health
organ
sever
institut
countri
throughout
africa
main
object
andi
promot
sustain
africanl
health
product
innov
address
african
public
health
need
effici
use
local
knowledg
assembl
research
network
build
capac
support
econom
develop
initi
launch
network
form
associ
sever
african
laboratori
consid
center
excel
date
andi
carri
facilit
function
rather
direct
funder
research
howev
attract
signific
sustain
fund
drive
effort
aim
attain
intend
goal
necess
program
thrive
partnership
industri
develop
specif
gene
therapi
rare
africa
one
exampl
collabor
recent
establish
johnson
johnson
innov
base
boston
usa
antivir
gene
therapi
research
unit
locat
univers
witwatersrand
johannesburg
south
africa
http
wwwprnewswirecomnewsreleasesjohnson
cooper
research
carri
two
group
aim
develop
gene
therapi
treatment
chronic
hbv
infect
initi
good
exampl
support
african
scientist
aim
tackl
diseas
particular
import
africa
importantli
partnership
hing
offer
industri
partner
welldevelop
expertis
highlight
advantag
africa
invest
research
develop
abil
manag
gener
intellectu
properti
addit
signific
factor
motiv
industri
partner
research
african
research
set
although
licens
gene
therapi
technolog
pois
interest
phase
develop
use
properti
method
employ
base
ration
design
principl
versatil
enabl
applic
treatment
mani
diseas
import
africa
gene
therapi
potenti
applic
sever
diseas
caus
seriou
public
health
problem
contin
howev
challeng
imped
global
progress
gene
therapi
mainstream
clinic
applic
success
translat
gene
therapi
particularli
depend
achiev
effici
deliveri
therapeut
nucleic
acid
target
tissu
limit
toxic
ensur
specif
action
candid
therapeut
addit
technic
hurdl
need
overcom
factor
influenc
util
gene
therapi
africa
efficaci
altern
prevent
therapeut
manag
import
recent
develop
directli
act
antivir
cure
hepat
c
viru
infect
mean
use
gene
therapi
elimin
viru
less
like
discuss
nevertheless
gene
therapi
import
role
cur
small
molecul
drug
avail
diseas
caus
hbv
exampl
gene
therapi
may
well
import
elimin
viral
infect
african
import
case
hbv
persist
problemat
cccdna
stabl
unaffect
current
licens
drug
employ
gene
edit
approach
provid
mean
disabl
viral
transcript
templat
gene
edit
may
also
employ
render
cell
resist
infect
inactiv
provir
dna
major
factor
influenc
longterm
prospect
gene
therapi
africa
relat
practic
use
technolog
resourcepoor
set
gene
therapi
drug
complex
costli
produc
administ
use
set
financi
resourc
constrain
therefor
moot
protocol
special
sophist
facil
prepar
administr
gene
therapi
necessari
exampl
technolog
develop
ex
vivo
modif
hematopoiet
stem
cell
autolog
graft
figur
strategi
eleg
result
suggest
approach
may
coupl
gene
edit
render
cell
resist
infect
howev
center
africa
equip
carri
procedur
ideal
methodolog
becom
cheaper
protocol
simplifi
moreov
progress
technolog
develop
new
candid
drug
rapid
particularli
use
counter
emerg
pathogen
seriou
outbreak
caus
ebov
sever
acut
respiratori
syndrom
coronaviru
addit
technic
challeng
lack
legal
framework
regul
use
gene
therapi
may
also
hinder
africa
deriv
benefit
technolog
implement
comprehens
legisl
govern
gene
therapi
research
translat
clinic
remain
imper
divers
religi
ethic
moral
belief
africa
also
need
accommod
despit
hurdl
implement
legal
framework
gene
therapi
may
inform
prior
experi
develop
regul
pertain
biotechnolog
use
stem
cell
therapi
particip
develop
countri
especi
africa
implement
gene
therapi
excit
valuabl
extend
regul
gene
therapi
nonexist
loos
cover
legisl
relat
biotechnolog
ensur
appropri
legisl
place
implement
gene
therapi
paramount
eventu
realiz
potenti
field
africa
involv
african
countri
process
improv
capac
modern
medic
appli
molecular
biolog
assist
tackl
health
problem
contin
effect
enabl
knowledgebas
economi
develop
activ
field
gene
therapi
africa
current
modest
howev
strengthen
endeavor
prioriti
extens
benefit
contin
